| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.3 | 0.1 |
| Gross profit | 0.1 | 0.1 |
| Profit before tax | -0.2 | 0.0 |
| Net income | -0.2 | 0.0 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +85.0% |
|---|---|
| Gross margin | 55.0% |
| Operating margin | -62.9% |
10-Q filed with the SEC, OTC: BIOE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bio Essence Corp: key numbers
- Share price
- $0.4700Close, Nov 13
- Market cap
- $25.3M
- Shares outstanding
- 53.81MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bio Essence Corp
All →Bio Essence Leadership Change
Bio Essence Corp. appointed Thea Zhang and Geoff Fellows to its Board of Directors effective October 19, 2026, following approval by written consent from a majority of shareholders. In conjunction with these appointments, the company amended its bylaws to increase the maximum number of authorized directors from three to ten. The new directors bring experience in pharmaceutical operations, finance, and governance to the board.